Indications
Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1).
Composition
- Active substance
- sofosbuvir, velpatasvir, voxilaprevi
- International name (INN)
- sofosbuvir;velpatasvir;voxilaprevi
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vosevi
- Active substance
- sofosbuvir, velpatasvir, voxilaprevi
- ATC code
- J05A
- Therapeutic area
- Hepatitis C, Chronic
- Marketing authorisation holder